Specialized BioPharma accessioning team collaborates for quality assurance - Insights
At Mayo Clinic, quality is not an act, it’s a habit. This commitment extends into BioPharma Diagnostics, where a team of four quality assurance assistants and three lab processing assistants has recently come together as the BioPharma...
Mayo Clinic Laboratory and Pathology Research Roundup: July 9 - Insights
This week’s Research Roundup highlights the association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.
Phlebotomy Modules: Module 1 | Insights
Skip to Content MayoACCESS MayoLINK...
CPT codes and LOINC update: August 2024 - Insights
This page lists updates posted to Mayo Clinic Labs during the month of August.
CPT codes and LOINC update: May 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of May.
Mayo Clinic Laboratory and Pathology Research Roundup: May 14 - Insights
This week's research roundup feature: Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPNs) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies,...
Mayo Clinic Laboratory and Pathology Research Roundup: March 5 - Insights
This week's research roundup feature: Variants of uncertain significance (VUSs) in BRCA2 are a common result of hereditary cancer genetic testing. While more than 4,000 unique VUSs, comprised of missense or intronic variants, have been...
Dr. Pandey is a nuclear radiology researcher working with a team to develop a new radioactive tracer to detect prostate cancer.
April 2021 — Genitourinary Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Genitourinary Pathology.
Mayo Clinic Laboratory and Pathology Research Roundup: May 21 - Insights
This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.